AT-001

Phase 3Small molecule

AApplied Therapeutics, Inc.

AT-001 is one of 86 small molecule programs targeting Cardiomyopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CardiomyopathyActive, not recruiting

Oxidative StressActive, not recruiting

COVID-19Active, not recruiting

CardiomyopathyPhase 3

Active, not recruiting

Oxidative StressPhase 1

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

AT-001

AApplied Therapeutics, Inc.

Phase 3

1 2

Singulair

AstraZeneca

Preclinical

1 3

Nitrostat

VViatris Specialty LLC

Preclinical

1 4

SARS-COV-2 VACCINE

Moderna

Preclinical

2 5

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—6

Piperacillin/tazobactam

Pfizer

Preclinical

1 7

Orap

Teva

Preclinical

1 8

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

3 9

Blood Taken

HHospices Civils de Lyon

Preclinical

1 10

Antithrombin-III

Octapharma

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiomyopathy1 trial

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

Active, not recruiting·AApplied Therapeutics, Inc.·Phase 3·NCT04083339·675 enrolled

Oxidative Stress1 trial

Safety and Tolerability of Antioxidant (AT-001)for Reducing Brain Oxidative Stress

Completed·AAlltech Life Sciences Inc.·Phase 1·NCT01731093·24 enrolled

COVID-191 trial

Cardiovascular Effects of COVID-19

Completed·NNYU Langone Health·Phase 2·NCT04365699·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for AT-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AT-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AT-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Applied Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AApplied Therapeutics, Inc.

AT-001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiomyopathy1 trial

Oxidative Stress1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News